APGE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
APGE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Apogee Therapeutics has the Momentum Rank of 0.
Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Apogee Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael Thomas Henderson | director, officer: Chief Executive Officer | 421 KIPLING STREET, PALO ALTO CA 94301 |
Carl Dambkowski | officer: Chief Medical Officer | 221 CRESCENT ST., BUILDING 17, SUITE 102B, WALTHAM MA 02453 |
Mark C. Mckenna | director | 400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807 |
Jane Henderson | officer: Chief Financial Officer | C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
Nimish P Shah | director | 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018 |
Peter Evan Harwin | director | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Jones William A Jr | director | NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421 |
Fairmount Funds Management Llc | director | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Fairmount Healthcare Fund L.p. | director | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Healthcare Fund Ii L.p. | director | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
Tomas Kiselak | director | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Jennifer A. Fox | director | C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036 |
Andrew Gottesdiener | director | 3340 HILLVIEW AVE, PALO ALTO CA 94304 |
Fairmount Healthcare Co-invest Ii L.p. | director | 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428 |
From GuruFocus
By GuruFocus News • 01-29-2025
By GuruFocus News • 11-09-2024
By Marketwired • 12-10-2024
By GuruFocus News • 02-28-2025
By Marketwired • 10-16-2024
By GuruFocus News • 02-08-2025
By GuruFocus News • 03-03-2025
By GuruFocus News • 11-14-2024
By Marketwired • 03-03-2025
By Marketwired • 02-25-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.